申请人:——
公开号:US20020061853A1
公开(公告)日:2002-05-23
This invention provides caspase inhibitors having the formula
1
wherein Ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R
1
is hydrogen, CHN
2
, R, or —CH
2
Y; R is an optionally substituted group selected from an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group, or an heterocyclylalkyl group; Y is an electronegative leaving group; R
2
is CO
2
H, CH
2
CO
2
H, or esters, amides or isosteres thereof; Ar is an optionally substituted aryl group; and R
3
is hydrogen, an optionally substituted C
1-6
alkyl, F
2
, CN, aryl or R
3
is attached to Ar to form an unsaturated or partially saturated five or six membered fused ring having 0-2 heteroatoms. The compounds are useful for treating caspase-mediated diseases in mammals.
这项发明提供了具有以下结构的caspase抑制剂:
其中Ring A是可选择取代的哌啶、四氢喹啉或四氢异喹啉环;R1是氢、CHN2、R或—CH2Y;R是从脂肪基、芳基、芳基烷基、杂环基或杂环烷基中选择的可选择取代基;Y是电负离子离去基团;R2是CO2H、CH2CO2H或它们的酯、酰胺或同分异构体;Ar是可选择取代的芳基;R3是氢、可选择取代的C1-6烷基、F2、CN、芳基或R3连接到Ar以形成具有0-2个杂原子的不饱和或部分饱和的五元或六元融合环。这些化合物可用于治疗哺乳动物中的caspase介导的疾病。